Vectura Group plc is a global specialty pharmaceutical company focused on the development and manufacture of inhaled drug-delivery products for respiratory diseases. The firm’s core activities encompass the design and optimisation of drug-device combinations to address conditions such as asthma, chronic obstructive pulmonary disease (COPD) and other pulmonary disorders. Vectura’s expertise spans small-molecule formulations and biologic therapies, leveraging advanced aerosol science to improve patient outcomes.
Research and development at Vectura centers on a broad portfolio of inhalation platforms, including dry powder inhalers (DPIs), pressurised metered-dose inhalers (pMDIs), soft-mist inhalers (SMIs) and nebuliser systems. Its proprietary technologies focus on enhancing drug stability, consistent dose delivery and targeted lung deposition, supporting both novel assets and lifecycle management of established therapies.
In addition to in-house pipeline programmes, Vectura operates as a contract development and manufacturing organisation (CDMO), providing end-to-end services for pharmaceutical and biotech customers. Offerings include preclinical formulation, analytical testing, clinical-scale manufacturing and comprehensive regulatory support. The company’s manufacturing and development sites span the UK, Switzerland, the United States and India, enabling global service delivery.
Founded in 1996 and headquartered in Chippenham, England, Vectura has grown through strategic collaborations and acquisitions to establish a presence across Europe, North America and Asia. In late 2021, it became a wholly owned subsidiary of Philip Morris International. Its ordinary shares continue to trade in the United States on the OTC market under the ticker VEGPF.
AI Generated. May Contain Errors.
